42Z Stock Chart & Stats
€162.50
€3.90(2.46%)
At close: 4:00 PM EDT
€162.50
€3.90(2.46%)
Day’s Range― - ―
52-Week Range€30.40 - €184.60
Previous CloseN/A
Volume153.00
Average Volume (3M)875.00
Market Cap
€39.25B
Enterprise Value€36.75K
Total Cash (Recent Filing)€3.94B
Total Debt (Recent Filing)€641.93M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 11, 2026EPS Estimate
-2.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.86
Shares Outstanding214,336,410
10 Day Avg. Volume360
30 Day Avg. Volume875
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)9.28
Price to Sales (P/S)0.00
P/FCF Ratio-16.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€190.42Price Target Upside17.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-8.35
Revenue Forecast (FY)€109.49M
Bulls Say, Bears Say
Bulls Say
Phase III PDAC Results & FDA NDA AcceptanceNEJM‑published, statistically significant Phase III PDAC results and FDA NDA acceptance materially de‑risk the lead daraxonrasib program. This creates a durable regulatory pathway toward first approval, strengthens clinical credibility and supports investment in launch and label expansion over coming quarters.
Strong Liquidity And Committed CapitalA $3.9B cash balance plus up to $1.5B committed capital provides multi‑quarter funding for late‑stage trials, manufacturing scale‑up and commercial launch preparations. This balance sheet strength materially reduces near‑term financing pressure and supports sustained program execution.
Commercial And Launch ReadinessHaving an established sales force, field access and patient services and a prepared supply/distribution network meaningfully shortens time from approval to revenue capture. This durable operational readiness lowers execution risk and supports rapid commercialization if approvals occur.
Bears Say
Accelerating Cash Burn And Widening LossesMaterial negative operating and free cash flow and a steepening net loss profile indicate real cash consumption. Over time this increases the likelihood of further financing, dilutive capital raises or covenant constraints if trial or regulatory timing slips, pressuring strategic flexibility.
Substantially Higher Operating Expense BaseA permanently higher operating expense run‑rate—driven by stepped‑up clinical, manufacturing and commercial investments—raises the break‑even bar. Sustained elevated costs make the business more dependent on successful approvals and commercial execution to justify ongoing investment.
Regulatory Timing And Trial Integrity UncertaintiesUncertain EMA timing, deferred CRC strategy and EAP crossover risks can delay global launches and complicate registrational trial endpoints. These structural execution risks may push back peak revenues and require complex trial or label negotiations across jurisdictions.
Revolution Medicines News
42Z FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was €30.40 and its highest was €184.60 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is €39.25B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Nov 11, 2026 which is in 83 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Aug 05, 2026. The company reported -€2.645 earnings per share for the quarter, missing the consensus estimate of -€1.766 by -€0.879.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -2.12.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 214,336,410 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -€2.645 in its last earnings report, missing expectations of -€1.766. Following the earnings report the stock price went up 2.228%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in DE:42Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revolution Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€190.42 (17.18% Upside)
€190.42 (17.18% Upside)
Blogger Sentiment
Bullish
DE:42Z Sentiment 64%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
396.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
77.94%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
42Z Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive clinical and regulatory momentum: a pivotal Phase III PDAC result (published in NEJM) with FDA NDA acceptance, robust expanded access uptake, multiple encouraging lung cancer combination datasets (high ORRs, high DCRs and early durability signals), an advancing global Phase III program across indications, and a healthy balance sheet ($3.9B) to fund commercialization and aggressive development. Offsetting these positives were materially higher operating expenses, a widened quarterly net loss (partly driven by a $151M noncash warrant charge), and remaining uncertainties around European timelines, CRC strategy details (deferred to Q4), and potential trial integrity risks from broad EAP access. On balance, the clinical wins, regulatory progress and financial resources substantially outweigh the increased spend and uncertainties, supporting an overall optimistic view.View all DE:42Z earnings summaries42Z Stock 12 Month Forecast
Average Price Target
€190.42
▲(17.18% Upside)